• Member News

The AMR Centre secures £2.3m funding boost

The AMR Centre has received a significant funding package to support the expansion of its pipeline of new drugs to treat drug-resistant infections.

DISCOVERY PARK CHAIRMAN MARTINO PICARDO SHARES INSIGHT AT CONFERENCES

Science park leader to talk at UKSPA, Knowledge Exchange meeting & BioIntegrates

Arecor receives regulatory approval to initiate phase I clinical trial for ultra-rapid acting insulin product

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

Apply to present at the 2019 Babraham Investor Conference

Babraham Research Campus is offering companies seeking funding the opportunity to present at its 10th investor conference

N-Site Life Sciences Knowledge Portal is now free for all subscribers – new expert guidance updates available

N-Site is a unique knowledge portal which provides expert insight and expertise for organisations, professionals and academics in the life sciences sector. This resource is now free to all subscribers, reflecting our intention for this resource to be used by as many as possible, and offers over 85 Guidance Notes from FTI Consulting, Gill Jennings & Every and Taylor Wessing on the key issues affecting companies in the sector.

Arecor appoints Chief Financial Officer

Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.

Blue Earth Diagnostics celebrates five year anniversary

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs over 100 people in Europe and in the USA.

OXFORD BUS COMPANY AND THE OXFORD SCIENCE PARK FORM PARTNERSHIP FOR ON-DEMAND SERVICE

Oxford, UK, March 5 2019 - Oxford Bus Company and The Oxford Science Park have formed a partnership to strengthen the PickMeUp on-demand minibus service in the Eastern Arc of the city.

Applications now open for the second Accelerate@Babraham life-science start-up competition

Life science start-ups are invited to apply for the opportunity to win access to the Babraham Research Campus bio-incubator facilities, plus an extended programme of support and mentoring.

Iksuda Therapeutics and Femtogenix sign license agreement

Agreement gives Iksuda access to Femtogenix’s therapeutic payloads to advance lead ADC for difficult-to-treat solid tumours